Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
Identifieur interne : 000580 ( Pmc/Curation ); précédent : 000579; suivant : 000581Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
Auteurs : Andrew J. Broadbent [États-Unis] ; Kanta Subbarao [États-Unis]Source :
- Current opinion in virology [ 1879-6257 ] ; 2011.
Abstract
Reflecting on the 2009 H1N1 pandemic, we summarize lessons regarding influenza vaccines that can be applied in the future. The two major challenges to vaccination during the 2009 H1N1 pandemic were timing and availability of vaccine. Vaccines were, however, well-tolerated and immunogenic, with inactivated vaccines containing 15μg of HA generally inducing antibody titers ≥1:40 in adults within 2 weeks of the administration of a single dose. Moreover, the use of oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3.75 or 7.5μg HA being immunogenic. Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually.
Url:
DOI: 10.1016/j.coviro.2011.08.002
PubMed: 22125588
PubMed Central: 3224079
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000580
Links to Exploration step
PMC:3224079Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J." last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22125588</idno><idno type="pmc">3224079</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224079</idno><idno type="RBID">PMC:3224079</idno><idno type="doi">10.1016/j.coviro.2011.08.002</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000580</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000580</idno><idno type="wicri:Area/Pmc/Curation">000580</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000580</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J." last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author></analytic><series><title level="j">Current opinion in virology</title><idno type="ISSN">1879-6257</idno><idno type="eISSN">1879-6265</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P2">Reflecting on the 2009 H1N1 pandemic, we summarize lessons regarding influenza vaccines that can be applied in the future. The two major challenges to vaccination during the 2009 H1N1 pandemic were timing and availability of vaccine. Vaccines were, however, well-tolerated and immunogenic, with inactivated vaccines containing 15μg of HA generally inducing antibody titers ≥1:40 in adults within 2 weeks of the administration of a single dose. Moreover, the use of oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3.75 or 7.5μg HA being immunogenic. Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually.</p></div></front></TEI><pmc article-type="research-article" xml:lang="en"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101560941</journal-id><journal-id journal-id-type="pubmed-jr-id">39304</journal-id><journal-id journal-id-type="nlm-ta">Curr Opin Virol</journal-id><journal-title-group><journal-title>Current opinion in virology</journal-title></journal-title-group><issn pub-type="ppub">1879-6257</issn><issn pub-type="epub">1879-6265</issn></journal-meta><article-meta><article-id pub-id-type="pmid">22125588</article-id><article-id pub-id-type="pmc">3224079</article-id><article-id pub-id-type="doi">10.1016/j.coviro.2011.08.002</article-id><article-id pub-id-type="manuscript">NIHMS322723</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Broadbent</surname><given-names>Andrew J.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Subbarao</surname><given-names>Kanta</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</aff><author-notes><corresp id="FN1"><label>*</label>Corresponding Author: Kanta Subbarao, MD, MPH, Chief, Emerging Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, Bldg 33, Room 3E13C.1, 33 North Drive, MSC 3203, Bethesda, MD 20892-3203, Phone: +1 301-451-3839, Fax: +1 301-480-4749, <email>ksubbarao@niaid.nih.gov</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>8</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2012</year></pub-date><volume>1</volume><issue>4</issue><fpage>254</fpage><lpage>262</lpage><self-uri xlink:href="http://www.sciencedirect.com/science/article/pii/S1879625711000769"></self-uri><abstract><p id="P2">Reflecting on the 2009 H1N1 pandemic, we summarize lessons regarding influenza vaccines that can be applied in the future. The two major challenges to vaccination during the 2009 H1N1 pandemic were timing and availability of vaccine. Vaccines were, however, well-tolerated and immunogenic, with inactivated vaccines containing 15μg of HA generally inducing antibody titers ≥1:40 in adults within 2 weeks of the administration of a single dose. Moreover, the use of oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3.75 or 7.5μg HA being immunogenic. Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually.</p></abstract><kwd-group><kwd>2009 H1N1</kwd><kwd>pandemic</kwd><kwd>influenza</kwd><kwd>vaccines</kwd></kwd-group><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>Z99 AI999999 || AI</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000580 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000580 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3224079
|texte= Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:22125588" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |